Stockreport

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Context Therapeutics Inc.  (CNTX) 
PDF Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific [Read more]